Wire · operational-macro
FDA Approves Talazoparib Combination for Prostate Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 October 2026 · Fusion42 review
The FDA approved the combination of talazoparib and enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer patients with homologous recombination repair gene mutations based on the positive findings from the phase 3 TALAPRO-3 clinical trial showing significant improvement in radiographic progression-free survival.
This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 26 Oct 2026 and 28 Oct 2026.
◆ ◆ The Wire takeaway
You now have an FDA-approved combination therapy expanding treatment options for metastatic prostate cancer patients with specific gene mutations. Biomarker testing has become crucial to qualify patients and compete in this evolving market.
◆ Coverage
10 sources · first reported 26 Oct 2026 · latest 28 Oct 2026
◆ Related on Wire
◆ Topics